Benign paroxysmal positional vertigo medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 51: Line 51:
===Benign paroxysmal positional vertigo===
===Benign paroxysmal positional vertigo===


* Preferred regimen : [[Betahistine]]  24 mg PO q12h for 7 days  
* Preferred regimen : [[Betahistine]]  24 mg PO q12h for 7 days
*
**
**



Revision as of 15:45, 5 March 2019

Benign paroxysmal positional vertigo Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Benign Paroxysmal Positional Vertigo from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Benign paroxysmal positional vertigo medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Benign paroxysmal positional vertigo medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Benign paroxysmal positional vertigo medical therapy

CDC on Benign paroxysmal positional vertigo medical therapy

Benign paroxysmal positional vertigo medical therapy in the news

Blogs on Benign paroxysmal positional vertigo medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Benign paroxysmal positional vertigo medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

  • Pharmacologic medical therapy is recommended among BPPV patients who does not answer well to Epley maneuver and continue to have multiple vertigo attacks which reduces their quality of life.

Benign paroxysmal positional vertigo

  • Preferred regimen : Betahistine 24 mg PO q12h for 7 days

References

Template:WH Template:WS